Joan Ann Fissette of Freedom Thru Hypnosis to be Featured on Close Up Radio

BALLSTON LAKE, NEW YORK, UNITED STATES, April 30, 2021 /EINPresswire.com/ — Everything you need is already inside you. Change your path; change your life.

Joan Ann Fissette is an expert on hypnosis and the founder of Freedom Thru Hypnosis.

Joan Ann is a 5-PATH Advanced Transformational Hypnotist. She is a 1” percenter” as one of less than 500 hypnotists in the world who use these techniques.

“Hypnosis guides you to become who you were meant to be,” says Joan Ann. “We are client centered so our goal is to free each soul from the weight of the negative emotion caused by an unwanted habit, behavior, belief, or trauma. Hypnosis is efficient and effective because it taps into the power of the subconscious mind where our memories and emotions live. Hypnosis neutralizes old limiting beliefs that prevent us from living to our full potential.”

5-PATH Hypnotists teach clients how to identify their feelings and respond to them in healthy ways. Clients learn these techniques reading The Secret Language of Feelings, one of the two books offered in the 5-PATH program written by her mentor, Cal Banyon.

“Talk therapy works with the conscious mind so it takes much longer to effect change. Our belief system is more permanently changed at the subconscious level through hypnosis.”

Joan Ann helps people who wish to overcome life challenges to change their perceptions through a technique known as the Informed Child Technique.

“In a safe and secure environment, I guide them to the very first time their negative emotion occurred with the goal of neutralizing the emotion,” explains Joan Ann. “Just before the “incident” the adult self tells the younger self what the younger self needs to know to ensure revivifying the event is less traumatic. The event facts never change, but now insight allows revivification to occur with compassion”.

As part of her plan for success, Joan Ann also teaches clients 7th Path Self-Hypnosis so that clients may resolve future challenges through this daily practice.

“Depending on the needs of each client, weekly 5-PATH sessions will run 4-7 weeks long. Weight loss clients often move to bi-monthly, then monthly sessions and stay with me as long as they feel the need,” says Joan Ann.

“Our sessions involving forgiving others and then, forgiving self, have a profound effect on releasing any remaining negative emotion,” says Joan Ann. “Watching and feeling each client’s transformation is a gift that continues to inspire me.”

Clients often return to engage in Soul Entrainment or The Informing Soul work.

Close Up Radio will feature Joan Ann Fissette in an interview with Jim Masters on May 4th at 12pm EDT

Listen to the show on BlogTalkRadio

If you have a question for our guest, call (347) 996-3389

For more information, visit www.freedomthruhypnosis.com

Lou Ceparano
Close Up Television & Radio
+1 631-850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Alabama Mesothelioma Victims Center Has Endorsed Attorney Erik Karst of Karst von Oiste to be The-Go To-Compensation Expert for a Navy Veteran with Mesothelioma in Alabama-Compensation Might Exceed $1,000,000

"If your loved one has mesothelioma or suspected mesothelioma in Alabama-please call attorney Erik Karst of Karst von Oiste at 800-714-0303 to get your questions about compensation answered.”

— Alabama Mesothelioma Victims Center

MONTGOMERY , ALABAMA , USA, April 30, 2021 /EINPresswire.com/ — According to the Alabama Mesothelioma Victims Center, "We have endorsed, and we recommend attorney Erik Karst of the law firm of Karst von Oiste to be the-go to-compensation expert for a Navy Veteran with mesothelioma in Alabama. Erik Karst is one of the nation's most capable mesothelioma attorneys and he specializes in assisting Navy Veterans with this rare cancer caused by asbestos exposure. The typical Navy Veteran we are trying to identify served in the navy in the 1950s, 1960s or 1970s-and their primary asbestos exposure took place on a navy ship, submarine or at a navy shipyard where their ship or submarine was undergoing repairs or an overhaul. Shipyard exposure to asbestos can frequently be extreme. Financial compensation for a person like this might exceed a million dollars as attorney Erik Karst of Karst von Oiste is always happy to discuss at 800-714-0303.

"If you are the family of a Navy Veteran who has just been diagnosed with or his doctors suspect he has mesothelioma please do not impulsively play mesothelioma lawyer roulette-where more often than not-you do not end up with what you want or need. If your loved one has mesothelioma or suspected mesothelioma in Alabama-please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 to get your questions about mesothelioma compensation answered. We are certain you will be glad you did." www.karstvonoiste.com/

The Alabama Mesothelioma Victims Center also wants to emphasize their services are available statewide for a diagnosed victim of mesothelioma in Alabama in any community including Birmingham, Montgomery, Mobile, Huntsville, or Tuscaloosa. https://Alabama.MesotheliomaVictimsCenter.Com

For the best possible treatment options in Alabama-we strongly recommend the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital:

The University of Alabama’s Comprehensive Cancer Center in Birmingham. https://www.uab.edu/onealcancercenter/.

According to the US Center for Disease Control the average age for a diagnosed victim of mesothelioma is 72 years old. Frequently victims of mesothelioma are initially misdiagnosed with pneumonia. This year between 2500, and 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is attributable to exposure to asbestos.

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. Mesothelioma also happens in New Mexico. However, based on the calls the Mesothelioma Victims Center receives a diagnosed victim of mesothelioma could live in any state including Alabama. www.karstvonoiste.com/

High-risk work groups for exposure to asbestos in Alabama include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, manufacturing, or industrial workers, plumbers, electricians, auto mechanics, machinists, miners, or construction workers. Typically, the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s, or 1980’s. www.karstvonoiste.com/

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma.

Michael Thomas
Alabama Mesothelioma Victims Center
+1 800-714-0303
email us here


Source: EIN Presswire

Oklahoma US Navy Veterans Lung Cancer Advocate Has Endorsed Attorney Erik Karst of Karst von Oiste To Help a Navy Veteran with Lung Cancer in Oklahoma to Get Compensated-If They Had Navy Asbestos Exposure

"Most Navy Veterans or people who had exposure to asbestos in the service or at work prior to 1982 and who have recently been diagnosed with lung cancer never get compensated-even though they should.”

— Oklahoma US Navy Veterans Lung Cancer Advocate

OKLAHOMA CITY, OKLAHOMA , USA, April 30, 2021 /EINPresswire.com/ — According to the Oklahoma US Navy Veterans Lung Cancer Advocate, "Most Navy Veterans or people who had heavy exposure to asbestos in the service or at work prior to 1982 and who have recently been diagnosed with lung cancer never get compensated-even though many to most should. The $30 billion dollar-asbestos trust funds were set up for people like this too. To get the compensation job done for a person like this we have endorsed, and we recommend attorney Erik Karst of the law firm of Karst von Oiste. Erik Karst of the law firm of Karst von Oiste is one of the nation's most experienced asbestos exposure attorneys-and he gets results. For direct access to attorney Erik Karst of Karst von Oiste please call 800-714-0303 anytime. Compensation for a person like who we have described might exceed $100,000.

"If your husband or dad is a Navy Veteran or person with recently has been diagnosed with lung cancer in Oklahoma and they had significant exposure to asbestos in the navy or at work in the 1950s, 1960s or 1970s please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 to discuss compensation. As mentioned—compensation for a person like this might exceed $100,000. www.karstvonoiste.com/

The Oklahoma US Navy Veterans Lung Cancer Advocate’s free services are available to people with asbestos exposure lung cancer or mesothelioma in Oklahoma City, Tulsa, Norman, Broken Arrow, Lawton, Moore, Midwest City, Enid, Edmund, Moore, Stillwater, or anywhere in Oklahoma. https://Oklahoma.USNavyLungCancer.Com

High risk occupations for asbestos exposure in Oklahoma include US Navy Veterans, Fort Sill Army Base in Lawton, Tinker Air Force Base in Oklahoma City, and the U.S. Naval Ammunition Depot in McAlester, oil-gas production workers, power plant workers, public utility workers, oil refinery workers, plumbers, electricians, welders, machinists, millwrights, mechanics, auto brake technicians, construction workers. www.karstvonoiste.com/

According to the American Cancer Society for nonsmokers who have been exposed to asbestos in their workplace the risk of lung cancer is five times that of unexposed workers. https://www.cdc.gov/cancer/lung/statistics/index.htm.

Important Note from the US Navy Veterans Lung Cancer Advocate: “If your husband, dad, coworker or neighbor has just been diagnosed with lung cancer and you know they had significant exposure to asbestos in the navy, at a shipyard or while working at a factory, at power plant, public utility, or as a plumber, electrician welder, mechanic or any kind of skilled trades group in any state please have them call us anytime at 800-714-0303. Most people like this never get compensated-even though the asbestos trust funds were set up for them too. We are trying to change this sad fact. Frequently compensation for people like this might exceed $100,000.” https://USNavyLungCancer.Com

States with the highest incidence of lung cancer include Kentucky, West Virginia, Maine, Tennessee, Mississippi, Ohio, Indiana, Louisiana, Arkansas, Missouri, North Carolina, Rhode Island, Alabama, and Delaware. However, there are people with asbestos exposure lung cancer in Oklahoma. www.karstvonoiste.com/

For more information about asbestos exposure please visit the NIH’s website on this topic:
https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/asbestos/asbestos-fact-sheet.

Michael Thomas
Oklahoma US Navy Veterans Lung Cancer Advocate
+1 800-714-0303
email us here


Source: EIN Presswire

The Center for Rapid Recovery Will Open on May 1 as the Only Non-Government Permanent Vaccination Site in Hempstead

First Faith-Based community organization to provide vaccinations in communities of Color continuously

HEMPSTEAD, N.Y., USA, April 30, 2021 /EINPresswire.com/ — The Center for Rapid Recovery (CRR), a minority-focused, faith-based behavioral healthcare organization, will open on May 1 as the only non-government permanent vaccination site within the Village of Hempstead. Located at 312 Greenwich Street, this would be the first distribution site with "residency" within The Village of Hempstead—directly supporting communities of Color and all surrounding residents. It is also the first Faith-Based community organization to provide vaccinations in communities of Color continuously. The Center will provide both day and evening vaccination to this diverse community of Color.

Where and how people can sign-up for and access vaccines have direct implications for who will receive them. People living in underserved and disproportionately affected areas may face increased challenges accessing vaccines due to more limited resources available to navigate online sign-up systems, lack of transportation, and other access challenges.

CRR is committed to ensuring individuals can access the vaccine, making sure people receive clear information that explains how and when they can obtain the vaccine, and addresses any concerns or questions they have about the vaccine is essential to pre-and post-engagement planning. The Center integrates culturally competent and linguistically appropriate care in our outreach and service delivery by assisting in Creole, Spanish, and other native tongues to complete the mandated paperwork. It will partner with other community organizations to promote vaccinations and address vaccination hesitancy in Color communities by addressing questions and concerns.

As a respected and engaged community organization for over 25 years, CRR is well situated to be a leader in the fight for the community. It is focused on being a proponent of "our vaccinations for our community." CRR has incurred the cost to convert its facilities to address this pandemic with the full force and effort of its combined cultural history.

For more information, visit https://rapidrecovery.org/

END
# # #

Media Relations
PR Services
email us here


Source: EIN Presswire

Research Antibodies and Reagents Market Growth Continues With Increasing Investment In Medical R&D

Research Antibodies And Reagents Market Report 2021: COVID-19 Growth And Change To 2030

Research Antibodies And Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Research Antibodies And Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON , UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Increasing investment in medical and health research and development (R&D) is predicted to contribute to the growth of the research reagent market and research antibodies market. In the field of life science research, antibodies and reagents are essential components for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing. According to the American Association for the Advancement of Science’s (AAAS) statistics published in December 2019, the total investment in medical and health research in the US grew by 6.4%. The health industry invested $129.5 billion (66.7%), followed by federal agencies investments of $43 billion (22.2%), and $21.7 billion (11.2%) invested by foundations, state & local governments, academic research institutions, and voluntary health associations. Thus, increasing investment in healthcare research and development will increase the utilization of research antibodies and reagents.

However, the global research antibodies and reagents market is expected to decline from $11.79 billion in 2020 to $11.57 billion in 2021 at a compound annual growth rate (CAGR) of -1.9%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The research antibodies and reagents market is expected to then reach $14.59 billion in 2025 at a CAGR of 6%.

Read More On The Global Research Antibodies and Reagents Market Report:
https://www.thebusinessresearchcompany.com/report/research-antibodies-and-reagents-global-market-report-2020-30-covid-19-growth-and-change

The research antibody diagnostic reagents market consists of sales of research antibodies, reagents and related services by entities (organizations, sole traders and partnerships) that produce research antibodies and reagents to diagnose and treat different diseases. The revenue generated by the market includes the sales of research antibodies in the form of primary and secondary antibodies extracted from sources such as mouse, rabbit and others, and reagents like stains & dyes, media & serum, fixatives, buffers, probe, solvents, enzymes and others. The companies involved in the research antibodies and reagents market are primarily engaged in developing antibodies and reagents for the application of proteomics, genomics, drug discovery and development by the pharmaceutical & biotechnology industries, academic & research institutes and contract research organizations.

The research antibodies and reagents market covered in this market is segmented by technology into western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), multiplex immunosorbent assay, immunoprecipitation, others; by application into proteomics, drug discovery & development, genomics; by end-user into pharmaceutical & biotechnology industry, academic & research institutes, contract research organizations (CROS).

Major players in the research reagent and antibody industry are Becton Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann La-Roche Ltd, Merck KGaA, PerkinElmer Inc., Lonza Group AG, Abcam plc, GenScript Biotech Corporation, and Bio-Techne Corporation.

Research Antibodies And Reagents Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides research antibodies and reagents market overview, forecast research antibodies and reagents market size and growth for the whole market, research antibodies and reagents market segments, and geographies, research antibodies and reagents market trends, research antibodies and reagents market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Research Antibodies and Reagents Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3418&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Scientific Research And Development Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/scientific-research-and-development-services-global-market-report-2020-30-covid-19-impact-and-recovery

Animal Testing And Non-Animal Alternative Testing Market – By Type (Animal Type, Industrial Application), Drivers, Restraints, Global Opportunities And Strategies – Global Forecast To 2035
https://www.thebusinessresearchcompany.com/report/animal-testing-and-non-animal-alternative-testing-market

Global Biologics Market – By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/biologics-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Artificial Intelligence In Drug Discovery Market Growth To Be At A Rate Of 38% Through 2025

Artificial Intelligence (AI) In Drug Discovery Global Market Report 2021: COVID-19 Growth And Change To 2030

Artificial Intelligence (AI) In Drug Discovery Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Artificial Intelligence (AI) In Drug Discovery Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The global artificial intelligence in drug discovery market is expected to grow from $0.36 billion in 2020 to $0.47 billion in 2021 at a compound annual growth rate (CAGR) of 30.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The AI in drug discovery market size is expected to reach $1.69 billion in 2025 at a CAGR of 38%.

The rise in demand for a reduction in the overall time taken for the drug discovery process in the healthcare market is a key driver propelling the growth of the AI in pharma market size. Traditionally, it takes three to five years for animal models to identify and optimize molecules before they are evaluated in humans whereas start-ups based on AI have been identifying and designing new drugs in a matter of few days or months. For instance, in 2020, the British start-up Exscientia and Japan's Sumitomo Dainippon Pharma have used artificial intelligence to produce an obsessive-compulsive disorder (OCD) medication, decreasing the development time from four years to less than one year. The reduction in overall time taken for the drug discovery process drives the artificial intelligence in drug discovery market’s growth.

Read More On The Global Artificial Intelligence In Drug Discovery Market Report:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-drug-discovery-global-market-report-2020-30-covid-19-growth-and-change

The artificial intelligence in drug discovery market covered in this report is segmented by technology into deep learning, machine learning. The artificial intelligence (AI) in drug discovery market is also segmented by drug type into small molecule, large molecules; by therapeutic type into metabolic disease, cardiovascular disease, oncology, neurodegenerative diseases, others; by end-users into pharmaceutical companies, biopharmaceutical companies, academic and research institutes, others.

Major players in the artificial intelligence (AI) in drug discovery market are IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, Benevolent AI, Exscientia, Cyclica, and BIOAGE.

Artificial Intelligence (AI) In Drug Discovery Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides artificial intelligence in drug discovery market overview, forecast artificial intelligence in drug discovery market size and growth for the whole market, artificial intelligence in drug discovery market segments, and geographies, AI in drug discovery market trends, artificial intelligence in drug discovery market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Artificial Intelligence In Drug Discovery Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
AI In Pharma Global Market Report 2021: COVID-19 Growth And Change
https://www.thebusinessresearchcompany.com/report/ai-in-pharma-global-market-report

Biophotonics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biophotonics-global-market-report-2020-30-covid-19-growth-and-change

Scientific Research And Development Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/scientific-research-and-development-services-global-market-report-2020-30-covid-19-impact-and-recovery

Artificial Intelligence Services Global Market Report 2021: COVID-19 Growth And Change to 2030
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-services-market-global-report-2020-30-covid-19-growth-and-change

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Anatomic Pathology Equipment And Consumables Market Trends Include Investment In New Technologies For Efficiency

Anatomic Pathology Equipment And Consumables Market Report 2021: COVID-19 Growth And Change To 2030

Anatomic Pathology Equipment And Consumables Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Anatomic Pathology Equipment and Consumables Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Companies in the anatomic pathology equipment and consumables market are increasingly investing in new technologies for better efficiency and reducing the time taken to conduct these tests. Companies such as Biogenex have developed automated staining technology such as Xmatrx and i6000 diagnostics for diverse laboratory needs. Xmatrx systems offer standardized processes from baking through final glass coverslip for staining and prevent cross-contamination and i6000 diagnostics is a high-throughput system for special staining of clinical samples in molecular pathology laboratories. The i6000 diagnostics possesses a staining capacity of 200 slides in 8 hours (60 slides in 3 hours).

In June 2019, PHC Holdings Corporation acquired the anatomical pathology business of Thermo Fisher Scientific Inc for $1.14 billion. The acquired anatomical pathology business is expected to work as a new self-governing business named Epredia that will proceed to work as a leading global provider of comprehensive solutions in the anatomical pathology field, including instruments, consumables, and microscope slides.

Read More On The Global Anatomic Pathology Equipment And Consumables Market Report:
https://www.thebusinessresearchcompany.com/report/anatomic-pathology-equipment-and-consumables-global-market-report-2020-30-covid-19-growth-and-change

The global anatomic pathology equipment and consumables market is expected to grow from $17.46 billion in 2020 to $18.95 billion in 2021 at a compound annual growth rate (CAGR) of 8.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The anatomic pathology market size is expected to reach $26.31 billion in 2025 at a CAGR of 9%.

Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated.

The equipment and consumables for anatomic pathology testing market covered in this report is segmented by products & services into instruments, consumables, services; by application into disease diagnosis, cancer, other diseases, medical research; by end-use into hospital laboratories, clinical laboratories, others.

Anatomic Pathology Equipment and Consumables Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides anatomic pathology equipment and consumables market overview, forecast anatomic pathology equipment and consumables market size and growth for the whole market, anatomic pathology equipment and consumables market segments, and geographies, anatomic pathology equipment and consumables market trends, anatomic pathology equipment and consumables market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Anatomic Pathology Equipment And Consumables Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3410&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Pharma Microbiology Testing Kits Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-market-global-report-2020-30-covid-19-growth-and-change

Telemedicine Services Market – By Technology (Real Time, Store and Forward), By Application (Telecardiology, Telepsychiatry, Teledermatalogy, Teleradiology, Telepathology, Other Telemedicine Services) And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/telemedicine-services-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

A Major Biosimilar Monoclonal Antibodies Market Driver Is The Prevalence Of Chronic Diseases

Biosimilar Monoclonal Antibodies Market Report 2021: COVID-19 Growth And Change To 2030

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 30, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American cancer society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market.

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products.

Read More On The Global Biosimilar Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

The global biosimilar monoclonal antibodies market is expected to grow from $3.52 billion in 2020 to $4.33 billion in 2021 at a compound annual growth rate (CAGR) of 23%. The biosimilar antibodies market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MAbs biosimilars market size is expected to reach $10.92 billion in 2025 at a CAGR of 26%.

The biosimilar monoclonal antibodies market covered in this report is segmented by type into synthetic chemicals, biopharmaceuticals, others, by application into chronic & autoimmune diseases, oncology, others, and by compound into Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab.

Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited.

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides biosimilar MAbs market overview, forecast biosimilar MAbs market size and growth for the whole market, biosimilar MAbs market segments, and geographies, biosimilar MAbs market trends, biosimilar MAbs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Biosimilar Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Monoclonal Antibodies (MAbs) Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-mabs-global-market-report

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global-market-report-2020-30-covid-19-growth-and-change

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

SHAREHOLDER ALERT: Law Offices of Timothy L. Miles is Investigating Clover Health Investments, Corp.

The Law Offices if Timothy L. Miles Is Investigating of Clover Health Investments, Corp. (Nasdaq: CLOV)

Nationally Recognized Shareholder Rights Attorney Timothy L. Miles Has Achieved the Recognition of American’s Most Honored Lawyers 2020 – Top 1%

Nationally Recognized Shareholder Rights Attorney Timothy L. MIles

SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles is Investigating Clover Health Investments, Corp. (CLOV) on Behalf of Shareholders

We fight everyday, as we have the last 20 yesrs, to protect shareholder rights, enhance shareholder protections, recover losses for defrauded investors, and seek reform through enhanced governance”

— Timothy L. Miles

HENDERSONVILLE, TN, UNITED STATES, April 30, 2021 /EINPresswire.com/ — The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 20 years is investigating Clover Health Investments, Corp. (NASDAQ: CLOV) on behalf of shareholders to determine whether certain Clover officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Clover Health provides medical insurance services.

If you suffered a loss due to Clover Health’s misconduct, click here.

Clover Health Investment, Corp. (CLOV) Misled Shareholders Ahead of Going Public

According to a class action complaint filed (commenced on February 10, 2021 in the Middle District of Tennessee and is captioned Yaniv v. Clover Health Investments, Corp., No. 21-cv-00109) against Clover Health, on October 6, 2020, the Company issued a press release announcing plans to become a publicly traded company via a merger with Social Capital Hedosophia Holdings Corp. III ("SCH"). SCH was a special purpose acquisition company (SPAC) that traded on the NYSE under IPOC.

On January 7, 2021, Clover and SCH announced it had completed the business combination and that shares of Clover would trade on NASDAQ under ticker symbol CLOV the next day. On February 4, 2021, Hindenberg Research published a report revealing "how Clover Health and its Wall Street celebrity promoter, Chamath Palihapitiya, misled investors about critical aspects of Clover's business in the run-up to the company's SPAC go-public transaction last month." Notably, Hindenberg revealed that Clover's business model and software offering "are under active investigation by the Department of Justice (DOJ), which is investigating at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals." On this news, shares of Clover dropped more than 12% from $13.95 on February 3, 2021, to $12.23 on February 4, 2021, representing a loss of $700 million in market capitalization. The stock continued to tumble and now trades at just $8.50.

Clover Health Shareholders Urged to Contact the Firm

If you purchased Clover securities, have information, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Timothy L. Miles, Esquire, at 615-587-7384, Toll-Free at 855-846-6529, or by email to tmiles@timmileslaw.com. If you inquire by email please include your mailing address, telephone number, and the number shares owned.

About Timothy L. Miles

Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Last year, Mr Miles was recognized as a 2020 Top Ranked Lawyer; 2020 Top Rated Litigator; and a 2020 Elite Lawyer of The South by Martindale-Hubbell® and ALM. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Awards: Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2021); Top Rated Lawyer by Martindale-Hubbell® and ALM (2019-2021); Elite Lawyer of The South by Martindale-Hubbell® and ALM (2019-2020); Member of the Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association (2017-2019); AV® Preeminent™ Rating by Martindale-Hubble® (2014-2020); PRR AV Preeminent Rating on Lawyers.com (2018-2020); The Top-Rated Lawyer in Litigation™ for Ethical Standards and Legal Ability (Martindale-Hubble® 2015); Lifetime Achievement Award by Premier Lawyers of America (2019); Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019-2020); Superb Rated Attorney (Avvo); Avvo Top Rated Lawyer for (Avvo 2017-2020). Mr. Miles has authored numerous publications advocating for shareholdings including most recently: Free Portfolio Monitoring Services Offered by Plaintiff Securities Firms Provides Significant Benefits to Investors (Timothy L. Miles, Dec. 3, 2019).

Contact:
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
124 Shiloh Ridge
Hendersonville, TN 37075
Telephone: (855-846-6529)
Email: tmiles@timmileslaw.com
Website: www.timmileslaw.com

Leading the Fight to Protect Shareholder Rights for Over 19 Years

Timothy Lee. Miles
Law Offices Of Timothy L. Miles
+1 6155877384
email us here
Visit us on social media:
Facebook
LinkedIn

Nationally Recognized Shareholder Rights Attorney Timothy L. Miles Has Achieved the Recognition of American’s Most Honored Lawyers 2020 – Top 1%


Source: EIN Presswire

WIN's Digital Display Precision Predictor biomarker to guide cancer targeted therapy & predict response duration

WIN Consortium announces publication of the Digital Display Precision Predictor global biomarker prototype for cancer patients in NPJ Precision Oncology

VILLEJUIF, FRANCE, April 30, 2021 /EINPresswire.com/ —
The Worldwide Innovative Network in personalized cancer medicine consortium – WIN Consortium announces the publication of the Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in NPJ Precision Oncology (10.1038/s41698-021-00171-6)

Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic approach used for most targeted therapies provides limited treatment options, with a binary "yes/no" expected response to a drug and no recommendation for which treatment, among a range of possible options, is likely to be the best option for a particular patient.

The Digital Display Precision Predictor (DDPP), is a biomarker strategy and tool able to predict the duration of progression-free survival (PFS) for multiple targeted treatments for patients with advanced/metastatic cancers, based on the comprehensive investigation of the whole transcriptome (the gene expression profile of the tumor compared to that of normal tissue).
DDPP is based on: 1) the exploration of the whole transcriptome (20,000 genes) providing insight about the status of activation of almost all drug targets in the context of the network of genes or pathways that drive tumor progression; 2) the data can be obtained from a single assessment requiring very small amounts of tumor and analogous normal tissues; and 3) the prediction of the duration of the time until tumor progression (PFS) under a specific therapeutic regimen.

"One of the main challenges of finding new biomarkers is that they are built in a relatively small number of patients treated with the same drug (from the WINTHER trial), for whom both molecular profiles (from tumor and analogous normal tissues) and PFS data were available," said Dr. Josep Tabernero, Vice-Chairman and Chairman of Scientific Advisory Board of WIN, Director, Vall d'Hebron Institute of Oncology, VHIO (Spain) and past ESMO President (2018-2019).

"The DDPP is potentially a new global biomarker tool that can apply to any type of cancer drug used alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer," concluded Dr. Richard L. Schilsky, Chairman of WIN.

__________________________________________________________________________________
About WIN Consortium
WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 35 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations and patient advocates spanning 19 countries and 4 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.

Vladimir Lazar, MD, PhD
Worldwide Innovative Network WIN Consortium
+33 6 61 09 15 22
vladimir.lazar@winconsortium.org
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire